Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Thursday

Verrica Pharmaceuticals (NASDAQ:VRCA) is expected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $1.30 million for the quarter.

Verrica Pharmaceuticals Stock Down 1.4 %

Shares of NASDAQ VRCA opened at $0.64 on Tuesday. Verrica Pharmaceuticals has a twelve month low of $0.59 and a twelve month high of $11.41. The firm has a market cap of $29.19 million, a P/E ratio of -0.35 and a beta of 1.47. The company has a 50 day moving average of $0.69 and a 200 day moving average of $1.22.

Institutional Investors Weigh In On Verrica Pharmaceuticals

An institutional investor recently raised its position in Verrica Pharmaceuticals stock. Bank of America Corp DE grew its holdings in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 347.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 143,818 shares of the company’s stock after acquiring an additional 111,678 shares during the period. Bank of America Corp DE owned about 0.32% of Verrica Pharmaceuticals worth $101,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 42.45% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on VRCA. Royal Bank of Canada lowered shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $11.00 to $2.00 in a research note on Tuesday, November 5th. HC Wainwright lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Friday, December 20th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.50.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.